Answers are grounded in this paper and cite their sources.
Purpose To evaluate the association between BRAFi/MEKi and Stevens–Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) using disproportionality analysis and case reports. Methods Case–non‐case reports (PubMed/Embase/Cochrane, up to June 2025) and FAERS data (Q1 2004–Q2 2025) were analyzed. Disproportionality signals were assessed using reporting odds ratio (ROR) and information component (IC). Included 154 SJS/TEN cases (17 from the literature, 139 from FAERS: SJS = 95, TEN = 44). Results Vemurafenib (BRAFi) and cobimetinib (MEKi) showed significant SJS/TEN risk. Median onset age: 58 years; median latency: 13 days (SJS: 11, TEN: 22). Mortality: 14.0% (18/129 cases; SJS: 8.6%, TEN: 31.8%). Conclusion BRAFi/MEKi are associated with SJS/TEN risk, necessitating vigilant monitoring and early intervention to mitigate severe outcomes.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: